BeiGene, Ltd., a global biopharmacy company, has been busy in the field of oncology. Amid various profit reports, they showcased an impressive hematology portfolio at EHA 2025. They received positive CHMP opinion for TEVIMBRA® a first-line treatment for nasopharyngeal cancer, which led to its approval in the US for first-line treatment of advanced esophageal squamous cell carcinoma in combination with chemotherapy. The company revealed a proposed name change to BeOne Medicines, shifting their global base to Switzerland, and changing their Nasdaq ticker symbol to “ONC". They gained a global licensing agreement for MAT2A Inhibitor, a treatment for extensive-stage small cell lung cancer. The company earned steady profits surpassing market estimates. BeiGene faced setbacks such as an unsuccessful trial for a key lung cancer drug and insider selling of stock. Despite these challenges, BeiGene has secured the patent for its drug BRUKINSA until 2037, thus ensuring future profitability
BeiGene, Ltd. News Analytics from Thu, 18 Jul 2024 07:00:00 GMT to Fri, 20 Jun 2025 07:00:00 GMT -
Rating 9
- Innovation 7
- Information 8
- Rumor -5
